Laddar populära aktier...
Huddlestock announced on Friday, March 22nd, that the company's client Stackby.
Redeye comments on the public offer to acquire Amniotics and the short-term capital obtained yesterd...
Pharma Equity Group (“PEG” or “the Company”) presented a Q4-report marked by advancements in the cli...
Nytt obligationslån Vi återupptar vår bevakning av Orexo efter att bolaget emitterat ett nytt säkers...
Brilliant Future, med en kund- och medarbetarundersökningsplattform, ökade nettoomsättningen till 89...
37% y-o-y ARR growth with 118% NRR in Q4 Lifting '24e-'26e ARR by 6-8%, EBITDA largely unchanged New...
FY'24 guidance reiterated as expected; better FCF the main surprise Progress on path to profitabilit...
Redeye comments on Sleep Cycle’s Capital Markets Day (CMD), including the revised financial targets.
Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2023 on the 20th of M...
ARR and P&L headline items known, FCF better vs. ABGSCe FY'24 guidance reiterated (as expected) Expe...
Redeye comments on MGI’s record sales figures for February, representing an organic growth of 25%, u...
Redeye comments on Flexion Mobile's Q4 2023 report, which aligned with preliminary figures.
As expected, IOVaxis excercised the option to license TG01 in Greater China.
Redeye leaves a comment following the recently announced updated data from the BEXMAB study with the...
Today’s announcement opens the possibility of international patent protection for DiviTum outside th...